Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 135, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.111217
Keywords
lncRNA; Osteosarcoma; Biomarker
Funding
- Shahid Beheshti University of Medical Sciences
Ask authors/readers for more resources
Osteosarcoma is a rare malignancy in children and adolescents, and understanding the underlying mechanisms of its evolution is crucial for improving management. Abnormal regulation of long non-coding RNAs has been observed in osteosarcoma, with various lncRNAs identified as potential targets for novel therapeutic approaches. Increasing research is focusing on utilizing lncRNAs to develop advanced treatments for osteosarcoma.
Osteosarcoma is rare malignancy of childhood and adolescence, with high morbidity and mortality despite accomplishment of diverse therapeutic modalities. Identification of the underlying mechanism of osteosarcoma evolution would help in better management of this rare malignancy. Lots of investigations have described abnormal regulation of long non-coding RNAs (lncRNAs) in clinical specimens of osteosarcoma and the established cell lines. This malignancy has been associated with over-expression of TUG1, LOXL1-AS1, MIR100HG, NEAT1, HULC, ANRIL and a number of other lncRNAs, while under-expression of lots of lncRNAs including LncRNA-p21, FER1L4, GAS5, LncRNA NR_136400 and LINC-PINT. Expression amounts of LUCAT1, LINC00922, SNHG12, FOXC2-AS1 and OIP5-AS1 lncRNAs have been associated with response to a number of chemotherapeutic agents. Taken together, lncRNAs are possible targets for proposing novel advanced therapeutic modalities for osteosarcoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available